Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes

Abstract

The sodium-dependent glucose transporter 2 (SGLT2) inhibitor remogliflozin etabonate (RE) was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled, parallel-group study. A total of 252 newly diagnosed and drug-naïve people with type 2 diabetes and glycated haemoglobin (HbA1c) concentrations of 7.0-≤9.5% (53-80 mmol/mol) were recruited. Participants were randomized to RE (100, 250, 500 or 1000 mg once daily or 250 mg twice daily), placebo or 30 mg pioglitazone once daily. The primary endpoint was change in HbA1c concentration from baseline. Secondary endpoints included changes in fasting plasma glucose, body weight and lipid profiles, safety and tolerability. We observed a statistically significant trend in the RE dose-response relationship for change from baseline in HbA1c at week 12 (p < 0.047). RE was generally well tolerated and no effects on LDL cholesterol were observed.

Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients

“…Data were sorted by first author, year of publication, country of the study, design, age range of the participants, total sample size, SGLT2 inhibitor, comparator, number of patients, dosage, and follow‐up duration (Table 1). 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 …”

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

“…SGLT2 inhibitors have been developed for the treatment of type 2 diabetes and a number are already available for clinical use [4][5][6][7][8][9]. Other SGLT2 inhibitors and dual SGLT2/SGLT1 inhibitors are being tested for the treatment of type 2 diabetes [10][11][12]. SGLT2 inhibitors lower fasting and postprandial glycaemia by enhancing urinary glucose excretion (UGE), a mechanism that is independent of insulin secretion [13].…”

Dental Stem Cell Differentiation Toward Endodermal Cell Lineages: Approaches to Control Hepatocytes and Beta Cell Transformation

“…The risk of developing this form of diabetes increases with age, obesity, and lack of physical activity [ 69 ]. Type 2 DM is controlled via the administration of drugs such as remoglifl ozinetabonate (RE), a sodium-dependent glucose transporter 2 (SGLT2) inhibitor [ 70 ], glucagon-like peptide-1 receptor agonist [ 71 ] and the use of newly developed techniques like resveratrol treatment [ 72 ]. Though insulin resistance may be improved with weight reduction and/or pharmacological treatment of hyperglycemia, it is seldomly restored to normal conditions ( Fig.…”